open access

Vol 66, No 2 (2016)
Research paper (original)
Published online: 2016-06-01
Get Citation

Mixed variant of mucinous breast cancer seen in the Oncology Centre in Krakow: clinical characteristics and treatment results in patients treated 1975–2005

Piotr Skotnicki, Łukasz Strzępek, Beata Sas-Korczyńska, Marian Reinfuss, Tomasz Walasek, Anna Patla
DOI: 10.5603/NJO.2016.0018
·
Nowotwory. Journal of Oncology 2016;66(2):97-102.

open access

Vol 66, No 2 (2016)
Original article
Published online: 2016-06-01

Abstract

Introduction. Mucinous breast carcinoma (MBC) accounts for approximately 2–3% of all breast cancer types. The purpose of this study is to present the clinico-pathological characteristics and treatment results in patients treated for mixed variant of MBC.

Material and methods. We analysed 50 patients with M-MBC treated between 1975 and 2005. The mean age was 64 years, and 86% patients presented with stage I or II breast cancer, involved lymph nodes were observed in 26%, and hormonal receptors positivity was found in 70% cases. All patients received surgical treatment: mastectomy (43 — 86%) or breast-conserving therapy (7 — 14%). The adiuvant treatment consisted of radiotherapy (24 — 48%), chemotherapy (13 — 26%).

Results. The 10-year disease-free survival (DFS) rate was 64%. Univariate and multivariate analyses showed that an independent statistically significant prognostic factor was the microscopic status of axillary lymph nodes (pN). 10-year DFS according to pN was 81.1% for pN0 and 15.4% for pN+. During the follow-up 16 patients (32%) developed distant metastases.

Conclusions. M-MBC is characterised by the following: high ratio of lower stage disease, hormonal receptors positivity and relatively lower incidence of involved axillary lymph nodes.  

Abstract

Introduction. Mucinous breast carcinoma (MBC) accounts for approximately 2–3% of all breast cancer types. The purpose of this study is to present the clinico-pathological characteristics and treatment results in patients treated for mixed variant of MBC.

Material and methods. We analysed 50 patients with M-MBC treated between 1975 and 2005. The mean age was 64 years, and 86% patients presented with stage I or II breast cancer, involved lymph nodes were observed in 26%, and hormonal receptors positivity was found in 70% cases. All patients received surgical treatment: mastectomy (43 — 86%) or breast-conserving therapy (7 — 14%). The adiuvant treatment consisted of radiotherapy (24 — 48%), chemotherapy (13 — 26%).

Results. The 10-year disease-free survival (DFS) rate was 64%. Univariate and multivariate analyses showed that an independent statistically significant prognostic factor was the microscopic status of axillary lymph nodes (pN). 10-year DFS according to pN was 81.1% for pN0 and 15.4% for pN+. During the follow-up 16 patients (32%) developed distant metastases.

Conclusions. M-MBC is characterised by the following: high ratio of lower stage disease, hormonal receptors positivity and relatively lower incidence of involved axillary lymph nodes.  

Get Citation
About this article
Title

Mixed variant of mucinous breast cancer seen in the Oncology Centre in Krakow: clinical characteristics and treatment results in patients treated 1975–2005

Journal

Nowotwory. Journal of Oncology

Issue

Vol 66, No 2 (2016)

Article type

Research paper (original)

Pages

97-102

Published online

2016-06-01

DOI

10.5603/NJO.2016.0018

Bibliographic record

Nowotwory. Journal of Oncology 2016;66(2):97-102.

Authors

Piotr Skotnicki
Łukasz Strzępek
Beata Sas-Korczyńska
Marian Reinfuss
Tomasz Walasek
Anna Patla

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl